ABOUT US
CH Life Science Private Limited, established on February 18, 2021, is a Bangalore-based pharmaceutical company
focused on innovative diagnostic technologies and
affordable medicine.
The company’s vision is to be a global leader in providing
high-quality, cost-effective pharmaceutical products to
improve the quality of life.
CH Life Science operates across research, development,
production, and marketing of in vitro diagnostics and
therapeutic solutions.
Mission and Vision
Mission :
CH Life Science Private Limited is dedicated to improving
global healthcare by providing high-quality, affordable
pharmaceutical products. The company aims to become a
recognized leader in domestic and international markets,
driving innovation in diagnostics and therapeutics while
enhancing the quality of life for society through accessible
and cost-effective solutions.
Future Vision :
CH Life Science aims to grow its portfolio by acquiring new
products, enhancing its therapeutic areas, and addressing
social issues through innovation and collaboration. The
company strives to become a global pharmaceutical leader
while maintaining a strong domestic presence
OUR PRODUCTS
Problem we are solving
High Diagnostic Costs: Making advanced diagnostics affordable
for all.
Limited Healthcare Access: Bridging gaps in underserved regions with cost-effective solutions.
Slow Disease Detection: Enhancing early and accurate disease diagnosis through innovative technologies.
Drug Development Challenges: Supporting efficient drug discovery with advanced R&D tools.
Company's Technology/Product, Including Technical CH Life Science specializes in:
- Antigen and Antibody Production Technologies: Developing advanced reagents for diagnostics and immunological testing
- Innovative Diagnostic Technologies: Creating in vitro diagnostic products for faster, more reliable results.
- Support for New Drug Discovery: Leveraging cutting-edge research to assist in pharmaceutical innovation.
- Regulatory-Approved Manufacturing Processes: Ensuring compliance with quality and safety standards for clinical performance studies, product authorization, and marketing.
Next-Generation Diagnostics
- Novel antigen-antibody technologies that improve diagnostic precision.
End-to-End Capabilities
- From R&D to clinical studies and regulatory compliance, enabling quicker time-to-market
Affordability
-
Emphasis on cost-effectiveness without compromising quality, ensuring accessibility to a
broader demographic.
Customer-Centric Design
- Collaboration with top physicians for product customization and trusted solutions.
Current TRL Stage of Your Technology/Product
CH Life Science’s technologies are currently at Technology Readiness Level (TRL) 7, with prototype demonstration in operational environments. The company is progressing toward TRL 8, aiming for full system integration, regulatory approvals, and market-ready deployment
- TRL 6: System/subsystem model or prototype demonstrated in a relevant environment (pre-clinical and validation stage).
- TRL 7: Prototype system demonstrated in an operational environment (initial field tests and clinical trials).
- Advancing to TRL 8: Focused on system integration and regulatory approvals for market readiness.
- Full Production Readiness: Processes are being optimized for large-scale manufacturing and distribution
- Regulatory Compliance: Preparing for final product certification to meet international and domestic standards
